X

Trial Profile

Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 14 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Trilaciclib (Primary)
Indications Advanced breast cancer; Triple negative breast cancer
Focus Adverse reactions
Sponsors G1 Therapeutics

Most Recent Events

05 Dec 2023 According to a G1 Therapeutics media release, data from this study presented in a poster session at San Antonio Breast Cancer Symposium (SABCS).
05 Dec 2023 Results presented in the G1 Therapeutics Media Release.
29 Nov 2023 According to a G1 Therapeutics media release, results from this study will be shared with the oncology community.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com